1. Home
  2. UGRO vs APVO Comparison

UGRO vs APVO Comparison

Compare UGRO & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo urban-gro Inc.

UGRO

urban-gro Inc.

HOLD

Current Price

$0.36

Market Cap

3.0M

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$1.07

Market Cap

21.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UGRO
APVO
Founded
2014
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
21.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
UGRO
APVO
Price
$0.36
$1.07
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
13.7M
1.1M
Earning Date
03-27-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$59,985,138.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$28.40
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.21
$1.00
52 Week High
$1.19
$109.80

Technical Indicators

Market Signals
Indicator
UGRO
APVO
Relative Strength Index (RSI) 61.91 37.76
Support Level $0.27 $1.00
Resistance Level $0.49 $1.11
Average True Range (ATR) 0.07 0.09
MACD 0.02 -0.01
Stochastic Oscillator 51.49 17.07

Price Performance

Historical Comparison
UGRO
APVO

About UGRO urban-gro Inc.

Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: